Semmax Financial Advisors Inc. Has $3.35 Million Stock Position in IQVIA Holdings Inc. $IQV

Key Points

• Semmax Financial Advisors Inc. increased its stake in IQVIA Holdings Inc. by 8.7% to own 19,005 shares, valued at approximately $3.35 million.
• Institutional investors now own 89.62% of IQVIA's stock, reflecting significant interest and positioning in the company.
• IQVIA's latest quarterly earnings revealed an EPS of $2.81, surpassing analyst expectations and indicating a year-over-year revenue increase of 5.3%.

Semmax Financial Advisors Inc. grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 8.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,005 shares of the medical research company's stock after acquiring an additional 1,518 shares during the period. Semmax Financial Advisors Inc.'s holdings in IQVIA were worth $3,351,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. American National Bank & Trust acquired a new stake in IQVIA during the first quarter worth approximately $26,000. Clal Insurance Enterprises Holdings Ltd lifted its position in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after acquiring an additional 131 shares during the last quarter. Golden State Wealth Management LLC lifted its position in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares during the last quarter. AllSquare Wealth Management LLC acquired a new stake in IQVIA during the first quarter worth approximately $33,000. Finally, ST Germain D J Co. Inc. lifted its position in IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Redburn Partners set a $214.00 price objective on shares of IQVIA in a research note on Wednesday, September 3rd. Jefferies Financial Group raised shares of IQVIA from a "hold" rating to a "buy" rating and boosted their target price for the stock from $195.00 to $225.00 in a research note on Tuesday. Finally, UBS Group increased their target price on IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Eighteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and an average price target of $229.64.

IQVIA Trading Down 1.8%

Shares of NYSE:IQV traded down $3.35 during mid-day trading on Friday, reaching $187.34. 946,284 shares of the company's stock were exchanged, compared to its average volume of 1,903,188. The firm has a market capitalization of $31.85 billion, a price-to-earnings ratio of 27.11, a PEG ratio of 2.02 and a beta of 1.32. The business's fifty day moving average price is $181.94 and its 200-day moving average price is $167.45. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $248.03.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. IQVIA's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.